Compare, Analyse Lupin with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs MYLAN (US) - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   MYLAN
EQUITY SHARE DATA
    LUPIN
Mar-20
MYLAN
Dec-18
LUPIN/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8823,474-   
Low Rs5051,912-   
Sales per share (Unadj.) Rs339.41,598.5-  
Earnings per share (Unadj.) Rs-5.943.4-  
Cash flow per share (Unadj.) Rs15.5342.7-  
Dividends per share (Unadj.) Rs6.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs276.71,729.3-  
Shares outstanding (eoy) m453.00514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.7 121.3%   
Avg P/E ratio x-116.662.0 -188.0%  
P/CF ratio (eoy) x44.87.9 570.5%  
Price / Book Value ratio x2.51.6 160.9%  
Dividend payout %-100.90-   
Avg Mkt Cap Rs m314,2011,385,529 22.7%   
No. of employees `00018.335.0 52.3%   
Total wages/salary Rs m29,8680-   
Avg. sales/employee Rs Th8,400.623,497.5 35.8%   
Avg. wages/employee Rs Th1,632.00-   
Avg. net profit/employee Rs Th-147.2638.1 -23.1%   
INCOME DATA
Net Sales Rs m153,748822,412 18.7%  
Other income Rs m4,8380-   
Total revenues Rs m158,585822,412 19.3%   
Gross profit Rs m24,849212,810 11.7%  
Depreciation Rs m9,702153,988 6.3%   
Interest Rs m3,63039,555 9.2%   
Profit before tax Rs m16,35519,267 84.9%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,571-3,065 -377.5%   
Profit after tax Rs m-2,69422,332 -12.1%  
Gross profit margin %16.225.9 62.5%  
Effective tax rate %70.8-15.9 -444.7%   
Net profit margin %-1.82.7 -64.5%  
BALANCE SHEET DATA
Current assets Rs m154,132459,234 33.6%   
Current liabilities Rs m92,252334,832 27.6%   
Net working cap to sales %40.215.1 266.1%  
Current ratio x1.71.4 121.8%  
Inventory Days Days8284 98.2%  
Debtors Days Days12993 138.5%  
Net fixed assets Rs m89,082159,534 55.8%   
Share capital Rs m906438 206.9%   
"Free" reserves Rs m124,4610-   
Net worth Rs m125,367889,699 14.1%   
Long term debt Rs m17,933960,271 1.9%   
Total assets Rs m249,8392,386,519 10.5%  
Interest coverage x5.51.5 370.2%   
Debt to equity ratio x0.11.1 13.3%  
Sales to assets ratio x0.60.3 178.6%   
Return on assets %0.42.6 14.4%  
Return on equity %-2.12.5 -85.6%  
Return on capital %8.73.2 274.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,9800-   
CASH FLOW
From Operations Rs m14,688170,897 8.6%  
From Investments Rs m11,070-88,335 -12.5%  
From Financial Activity Rs m-8,906-79,614 11.2%  
Net Cashflow Rs m16,8531,416 1,190.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.98 Rs / USD

Compare LUPIN With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN With: CADILA HEALTHCARE  WYETH  STERLING BIOTECH  ALKEM LABORATORIES  ELDER PHARMA  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views On News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks (Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond (Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell (Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond (Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

LUPIN SHARE PRICE


Jan 25, 2021 (Close)

TRACK LUPIN

MORE ON LUPIN

LUPIN - AUROBINDO PHARMA COMPARISON

COMPARE LUPIN WITH

FEATURED VIDEOS

Smallcap Revival: Should You Wait, Keep Holding, or Buy Now?

Crucial Week Ahead for the Indian Stock Market

Great vs Good: Which Stock Will Win in 2021?

Safest Assets in 2021 are Not What You Think...

More Featured Videos

MARKET STATS